US-CONGRESS BILLS-119s2658rs: Medication Affordability and Patent Integrity Act
The Medication Affordability and Patent Integrity Act introduces new requirements for drug pricing transparency and patent integrity, affecting FDA-regulated pharmaceutical manufacturers.
Aforeworn detected this change in the Pharmaceutical Manufacturing (FDA/DEA) space on July 30, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Medium urgency. Branded drug makers, generic/ANDA manufacturers, API & contract manufacturers, compounding outsourcing facilities (503B). should confirm how it applies to their specific situation before acting. There is a time constraint attached: Not specified in the excerpt; check the bill for effective dates.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmaceutical Manufacturing (FDA/DEA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
New obligations to report drug pricing information and address patent integrity issues; specific details on deadlines and penalties are not provided in the excerpt.
Who it affects
Branded drug makers, generic/ANDA manufacturers, API & contract manufacturers, compounding outsourcing facilities (503B).
What you must do
Review the full bill text to identify specific compliance obligations; prepare to adjust pricing and patent reporting processes.
Deadline
Not specified in the excerpt; check the bill for effective dates.
Source: https://www.govinfo.gov/app/details/BILLS-119s2658rs
Never miss a change like this again
Aforeworn watches Pharmaceutical Manufacturing (FDA/DEA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmaceutical Manufacturing (FDA/DEA)
- Ordering Schedule I and II Controlled Substances Using DEA Form 222; Technical Amendments
- Schedules of Controlled Substances: Placement of 3-Methoxyphencyclidine (1-(1-(3-Methoxyphenyl)cyclohexyl)piperidine) in Schedule I
- Designation of P2P Methyl Glycidic Acid as a List I Chemical
- Specific Listing for Hexahydrocannabinol, A Currently Controlled Schedule I Substance
- Exempt Chemical Preparations Under the Controlled Substances Act